MedTrace Logo

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

NCT06249152 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-01-20

No results posted yet for this study

Summary

Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.

Conditions

  • Open-angle Glaucoma (OAG)
  • Ocular Hypertension (OHT)
  • Glaucoma

Interventions

DRUG

QLS-111, 0.015%

QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.

DRUG

QLS-111, 0.030%

QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.

DRUG

QLS-111, 0.075%

QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.

DRUG

QLS-111 vehicle ophthalmic solution

Vehicle drops applied QPM for 14 days the BID for 14 days.

Sponsors & Collaborators

  • Qlaris Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Lisa Brandano · Qlaris Bio, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-21
Primary Completion
2024-12-20
Completion
2024-12-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06249152 on ClinicalTrials.gov